JUNE 2021LIFE SCIENCES REVIEW6In the last few years, new biotechnology studies have paved the way for novel treatment methods for rare and complex diseases. The fields of oncology, neurology, immunology, infectious diseases, or regenerative medicine have been the major drivers for innovative biotech research and development. No wonder the global biotechnology market that was valued at USD 752.88 billion in 2020 is expected to expand at a CAGR of 15.83 percent from 2021 to 2028. The critical contributor to such exponential growth of modern biotechnology is undoubtedly DNA sequencing. Simply put, it is the process of determining nucleotide variations pertaining to specific genetic diseases. This ultimately leads to better understanding and treatment of diseases. DNA sequencing also underpins a relatively new discipline--pharmacogenomics or the study of genome in drug response. Combining the principles of pharmacology and genomics supports the development of effective medications tailored to a person's genetic makeup. Needless to say, pharmacogenomics today has become one of the most important fields in biotechnology by supporting the notion of individualized drugs and discarding the concept of "one drug fits all patients."Cancer treatment has also made significant strides with the help of advanced biotechnology. Take immuno-oncology, for instance. This treatment method undermines the concept of directly attacking the tumors; instead, it promotes the idea of stimulating the body's own immune system to fight cancer. Several clinical studies have revealed that immune-oncology can change the face of cancer treatment not only by killing tumor cells but also by eliminating the chances of its re-emergence. These are just a few areas where modern biotechnology is doing wonders. It can open up new treatment avenues for several other disease types, which is probably why many biotech start-ups are emerging and indulging in research and development. This edition aims to provide readers insights into the recent developments in this field and the players that are really making the difference. Let us know your thoughts.EDITORIALChanging the Paradigm of Life SciencesCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com June - 21 - 2021 02, Issue - 05 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald Donovan*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comDean WinchesterVictor Cruz
< Page 5 | Page 7 >